Spots Global Cancer Trial Database for Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
Official Title: Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
Study ID: NCT01464177
Conditions
Study Description
Brief Summary: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The treatment comprises maximal safe resection followed by radiotherapy and chemotherapy. Despite appropriate management, 90% of the patients will develop relapse or progression. After progression, the median survival is 5.2 months (Stupp, 2009). The treatment of GBM relapse remains investigational. Reirradiation is an option in selected cases. The objective of this study is to compare 2 schemes of stereotactic hypofractionated radiotherapy in the management of recurrent GBM.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital das Clinicas da Faculdade de Medicina da USP, Sao Paulo, SP, Brazil
Contact Details
Name: Andre T Chen, M.D. / PhD
Affiliation: Hospital das Clinicas da Faculdade de Medicina da USP
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
